Vineet Laboratories Limited (NSE: VINEETLAB | BSE: 543298)

By Raveendran R | Updated on:

Source: Vineet Laboratories Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026)

Metrics for FY 2025-26 Ended Mar 31, 2026
Profit & Loss (₹ Cr)
Revenue
₹59.40 Cr (▼ 20.8%)
Prev Year: ₹75.00 Cr
Gross Profit
₹20.80 Cr (▲ 337.0%)
Prev Year: ₹4.76 Cr
Operating Profit
₹6.08 Cr (▲ N/M)
Prev Year: -₹18.78 Cr
Net Profit
₹1.11 Cr (▲ N/M)
Prev Year: -₹20.19 Cr
Ratios & Margins (% / x)
Gross Margin
35.02 % (▲ 2867 bps)
Prev Year: 6.35 %
Operating Margin
10.24 % (▲ 3528 bps)
Prev Year: -25.04 %
PAT Margin
1.87 % (▲ 2879 bps)
Prev Year: -26.92 %
ROCE
10.57 % (▲ 10377 bps)
Prev Year: -93.20 %
ROCE (3Y Avg)
-24.84 %
FY24–FY26 (3Y Avg)
ROE
2.43 % (▲ 14025 bps)
Prev Year: -137.82 %
ROA
0.89 % (▲ 2225 bps)
Prev Year: -21.36 %
Asset Turnover
0.48x (▼ 0.32 pts)
Prev Year: 0.79x
Balance Sheet (₹ Cr)
Total Assets
₹124.78 Cr (▲ 32.0%)
Prev Year: ₹94.54 Cr
Current Assets
₹98.83 Cr (▲ 46.7%)
Prev Year: ₹67.39 Cr
Total Liabilities
₹79.18 Cr (▼ 0.9%)
Prev Year: ₹79.89 Cr
Current Liabilities
₹67.28 Cr (▼ 9.6%)
Prev Year: ₹74.39 Cr
Total Debt
₹45.33 Cr (▲ 13.2%)
Prev Year: ₹40.05 Cr
Total Equity
₹45.60 Cr (▲ 211.3%)
Prev Year: ₹14.65 Cr
Working Capital
₹31.55 Cr (▲ N/M)
Prev Year: -₹7.00 Cr
Ratios & Margins (% / x)
Current Ratio
1.47x (▲ 0.56 pts)
Prev Year: 0.91x
Debt to Equity
0.99x (▼ 1.74 pts)
Prev Year: 2.73x
Debt to Assets
0.36x (▼ 0.06 pts)
Prev Year: 0.42x
Equity Multiplier
2.74x (▼ 3.72 pts)
Prev Year: 6.45x
Cash Flow (₹ Cr)
Operating Cash Flow
-₹12.24 Cr (▼ N/M)
Prev Year: ₹11.49 Cr
CapEx
₹1.20 Cr (▲ 14.3%)
Prev Year: ₹1.05 Cr
Free Cash Flow
-₹13.44 Cr (▼ N/M)
Prev Year: ₹10.44 Cr
Ratios & Margins (% / x)
FCF Margin
-22.63 % (▼ 3655 bps)
Prev Year: 13.92 %
Cash ROCE
-21.29 % (▼ 7831 bps)
Prev Year: 57.02 %
Cash ROE
-26.84 % (▼ 10527 bps)
Prev Year: 78.43 %
CF to Debt
-0.27x (▼ 0.56 pts)
Prev Year: 0.29x

📋 Quick Facts: Company Snapshot

Attribute Disclosed Detail
Official Company Name Vineet Laboratories Limited
Corporate Identity Number (CIN) L24304TG2016PLC112888
ISIN INE505Y01010
Stock Exchange Listing National Stock Exchange of India Limited (NSE: VINEETLAB) | BSE Limited (BSE: 543298)
Date of Incorporation November 2016 (Commencement of Commercial Production: 10.11.2016)
Registered Office Sy. No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana, 500074, India
Telephone +91-040-24128833
Official Investor Relations Email cs@vineetlabs.co.in
Managing Director Mr. Gaddam Venkata Ramana (DIN: 00031873)
Executive Director & Chief Financial Officer (CFO) Mr. Satyanarayana Raju Bhupathiraju (DIN: 02697880)
Whole Time Director Mr. Rajesh Kumar Kathulla (DIN: 05349717)
Company Secretary & Compliance Officer Mr. Ramesh Kumar Bandari (resigned effective May 29, 2026)
Industry / Sector Classification Pharmaceuticals & Fine/Specialty Chemicals (Drug Intermediates and Bulk Drugs)
Total Permanent Employees 108 employees on rolls (as on March 31, 2026)
Statutory Auditor M/s. NSVR & Associates LLP, Chartered Accountants (Firm Regn No. 008801S/S200060; casual vacancy filled by M/s SVRL & Co.)
Secretarial Auditor M/s. P. S. Rao & Associates, Practicing Company Secretaries (casual vacancy filled by M/s Aakanksha Dubey & Co.)
Cost Auditor M/s. KJU & Associates, Cost Accountants (casual vacancy filled by M/s Mannidi & Associates)
Internal Auditor M/s. V D P & Co, Chartered Accountants (subsequently M/s Krishna Reddy & Co effective November 4, 2026)
Registrar & Share Transfer Agent (RTA) M/s Venture Capital and Corporate Investments Private Limited, “AURUM”, 5th Floor, Plot No. 57, Jayabheri Enclave Phase – II, Gachibowli, Hyderabad – 500032, Telangana
Principal Banker HDFC Bank Limited

🏢 The Corporate Identity: Vineet Laboratories Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Vineet Laboratories Limited is a Hyderabad-based manufacturer specialising in advanced pharmaceutical intermediates, active pharmaceutical ingredient (API) precursors, bulk drugs, and fine specialty chemicals. The company operates in a single reportable operating segment comprising pharmaceutical intermediates, bulk drugs, and fine chemicals under Indian Accounting Standards (Ind AS 108). Its competitive positioning is anchored in multi-step organic synthesis, synthetic chemistry, process development, and commercial-scale chemical engineering.

During the fiscal year ended March 31, 2026 (FY 2025-26), the company underwent a corporate and operational turnaround coupled with recapitalisation. Confronted with industry-wide pricing pressure and elevated raw material costs from prior cycles, the management deliberately rationalised its operating portfolio. The company transitioned away from high-volume, commoditised chemical lines toward higher-margin, complex specialty molecules catering to pharmaceutical therapies and personal care applications.

The core business model relies on domestic and export supply agreements with formulators, innovator pharmaceutical companies, and generic manufacturers. Vineet Laboratories leverages dedicated chemical reactors, distillation systems, and quality control laboratories to provide chemistry-driven scale-up solutions that meet stringent domestic and international regulatory parameters.

The Founders, Promoters & Their Legacy

The promoter group is led by seasoned pharmaceutical professionals, prominently Mr. Gaddam Venkata Ramana and Mr. Satyanarayana Raju Bhupathiraju, supported by members of the extended promoter family and associated technical professionals. Mr. Gaddam Venkata Ramana, Managing Director, holds a Master of Science (M.Sc.) degree and possesses extensive leadership experience in synthetic chemical manufacturing, having previously served with Siris Limited before steering Vineet Laboratories from its inception.

Mr. Satyanarayana Raju Bhupathiraju serves as Executive Director and Chief Financial Officer, bringing deep administrative and governance oversight gained over decades of corporate experience. The promoter group maintains operational discipline, ensuring compliance with evolving technical frameworks, good manufacturing practices (GMP), and statutory corporate requirements. Key managerial personnel also include Mr. Rajesh Kumar Kathulla, who was appointed as Whole-Time Director effective July 21, 2026, contributing entrepreneurial experience across operations, project implementation, and business development.

The Journey: Corporate History & Key Milestones

Vineet Laboratories Limited was incorporated in 2016 under the Companies Act, 2013, with its registered office established in Hyderabad, Telangana. The company commenced commercial production on November 10, 2016, following the establishment of its chemical manufacturing infrastructure. The business was structured following a corporate demerger scheme involving Ortin Laboratories Limited, which contributed to the creation of its capital reserve.

Key corporate and operational milestones across the company’s operating timeline include:

  • November 2016: Incorporation and official commencement of commercial production at its active manufacturing facilities in Telangana.
  • Capital Demerger: Establishment of an initial capital reserve of ₹1.11 Crores arising from the demerger from Ortin Laboratories Limited.
  • Dual Exchange Listing: Listing of equity shares on both BSE Limited (Scrip Code: 543298) and the National Stock Exchange of India Limited (Symbol: VINEETLAB).
  • FY 2024-25 Stress Period: An industry downcycle resulting in revenue declining to ₹75.00 Crores and an operating loss before finance costs and tax of ₹16.80 Crores.
  • January–February 2026 Rights Issue: Execution of a rights issue offering 99,87,258 equity shares of face value ₹10 each at an issue price of ₹30 per share (including a premium of ₹20 per share), raising ₹29.96 Crores to recapitalise the balance sheet and expand working capital capacity.
  • FY 2025-26 Operational Turnaround: Full-year restoration of profitability, achieving an EBITDA of ₹8.49 Crores (margin of 14.29%) and a profit after tax of ₹1.11 Crores.

The Corporate Umbrella & Group Structure

Vineet Laboratories Limited operates as a standalone operating entity. As explicitly disclosed in Section 15 and Section 16 of the Directors’ Report, the company does not possess any subsidiaries, joint ventures, or associate companies. Consequently, reporting under Form AOC-1 is not applicable.

The company maintains arms-length commercial relationships with affiliated promoter-group corporate entities operating in adjacent life sciences, raw material synthesis, and trading sectors. These related entities include Vineet Life Sciences Private Limited, Organo Metalics Private Limited, Wohler Laboratories Private Limited, and Vineet Chem Trade Private Limited.

⚙️ The Business Engine: Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

In accordance with Ind AS 108 (Operating Segments), the company functions in a single reportable business segment: the manufacture of pharmaceutical intermediates, bulk drugs, and fine chemicals. All operational decision-making, resource allocation, and performance assessments conducted by the Chief Operating Decision Maker (CODM) are executed on an enterprise-wide basis.

Business Segment FY 2025-26 Revenue (₹ in Crores) % Share of Total Revenue FY 2024-25 Revenue (₹ in Crores) % Share of Total Revenue Latest YoY (%)
Manufactured Products (Drug Intermediates & Bulk Drugs) 57.27 96.41% 69.77 93.03% -17.92%
Sale of Services (Job Work & Chemical Processing) 10.57% 3.59% 93.20% 6.97% –
Total Revenue from Operations 59.40 100.00% 75.00 100.00% -20.80%

Revenue from operations totaled ₹59.40 Crores in FY 2025-26 compared with ₹75.00 Crores in FY 2024-25, representing a volume-driven decline of 20.80%. This contraction was a deliberate management strategy to eliminate commoditised, negative-margin product sales, reallocating capacity toward high-value intermediates.

The Product & Service Catalog (with Operational KPIs & Order Book)

The manufacturing capabilities of Vineet Laboratories encompass multi-step synthetic chemistry, alkylation, condensation, halogenation, and cyclisation reactions across three core therapeutic and specialty verticals:

  • Specialty API Intermediates: Intermediates for critical anti-retroviral therapies (specifically targeting Ritonavir and Lopinavir drug substances), advanced anti-fungal therapies (including intermediate steps for Voriconazole), and specialty anti-ulcer therapeutics.
  • Ophthalmic Intermediates: Chemical derivatives including Dorzolamide and Brinzolamide intermediate building blocks utilised by generic formulation manufacturers in anti-glaucoma ophthalmic solutions.
  • Personal Care & Specialty Ingredients: High-performance active ingredients comprising Piroctone Olamine (an anti-dandruff active), Avobenzone, and modern broad-spectrum ultraviolet (UV) filters including Tinosorb S and Ethylhexyl Triazone for premium sun-care and dermatological formulations.
  • Contract Manufacturing & Chemical Services: Custom chemical synthesis and job-work processing services utilizing the company’s reaction trains, generating ₹2.13 Crores in FY 2025-26.

The Names You Know: Key Brands & Flagship Portfolio

Brand / Product Name Category / Business Segment Target Market & Key Positioning
Ritonavir & Lopinavir Intermediates Specialty API Intermediates Global and domestic anti-retroviral therapy manufacturing chains.
Voriconazole Intermediates Specialty API Intermediates Critical systemic anti-fungal treatments.
Dorzolamide & Brinzolamide Intermediates Ophthalmic Intermediates Ophthalmic therapies reducing intraocular pressure in glaucoma patients.
Piroctone Olamine Personal Care Actives Active anti-dandruff ingredient for specialized hair-care and scalp formulations.
Avobenzone & Specialty UV Filters (Tinosorb S / Ethylhexyl Triazone) Specialty Personal Care Chemicals Dermatological sunscreens requiring high photostability and UV absorption.

The strategic expansion into personal care actives and UV filters provides structural diversification for Vineet Laboratories. Unlike pharmaceutical intermediate demand, which fluctuates based on government tender cycles and therapeutic inventory restocking, consumer personal care ingredients follow non-cyclical end-consumer demand patterns.

Mapping the Domestic & Global Reach (India vs. Exports)

During the fiscal year ended March 31, 2026, the company’s recorded revenue was concentrated entirely within the domestic Indian market, directly supplying domestic formulators and active exporters.

Geographic Market FY 2025-26 Revenue (₹ in Crores) % Share of Total Revenue FY 2024-25 Revenue (₹ in Crores) % Share of Total Revenue Latest YoY (%)
Domestic (India) 59.40 100.00% 74.99 100.00% -20.79%
Exports (Outside India) 0.00 0.00% 0.00 0.00% N/M
Total Revenue from Contracts with Customers 59.40 100.00% 75.00 100.00% -20.80%

As disclosed in the notes to the financial statements and the Directors’ Report, both Foreign Exchange Earnings and Foreign Exchange Outgo during FY 2025-26 stood at Nil (FY 2024-25: Nil). However, the company indirectly participates in global pharmaceutical supply chains, as its intermediate products are supplied to large Indian pharmaceutical export houses holding US FDA, EU-GMP, and WHO approvals.

The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices

The company’s operational infrastructure is centered in Telangana, India. Its primary physical assets include:

  • Registered & Corporate Office: Survey No. 11/A3, Saheb Nagar, Kurdu Village, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana – 500074.
  • Manufacturing Plant & Industrial Facilities: Located in the industrial corridors of Telangana (including facilities at Malkapur, Yadadri Bhuvanagiri district), equipped with glass-lined and stainless-steel reaction systems, multi-stage distillation columns, centrifuges, and effluent treatment facilities.
  • In-House Analytical Quality Control & Process Chemistry: Dedicated laboratories equipped with High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and wet chemical testing apparatus to monitor reactions and product specifications.

📊 The Financial Health: The Numbers Simplified

Multi-Year Financial Highlights (₹ in Crores)

A multi-year evaluation of operations highlights the operational correction executed in FY 2025-26 following the severe inventory destocking and price erosions encountered in FY 2024-25.

Financial Metric (₹ in Crores) FY 2025-26 FY 2024-25 FY 2023-24 Latest YoY (%)
Revenue from Operations 59.40 75.00 150.59 -20.80%
Other Income 0.10 1.99 0.36 -94.97%
Total Income 59.50 76.99 150.95 -22.72%
EBITDA (Excluding Other Income) 8.49 (16.28) 8.82 N/M
Operating Profit (EBIT) 6.08 (18.78) 6.41 N/M
Finance Costs 4.89 3.98 4.01 +22.86%
Depreciation and Amortisation 2.41 2.50 2.41 -3.60%
Profit / (Loss) Before Tax (PBT) 1.28 (20.78) 0.36 N/M
Profit / (Loss) After Tax (PAT) 1.11 (20.19) 1.03 N/M
Total Equity (Net Worth) 45.60 14.65 34.72 +211.26%
Total Borrowings (Debt) 45.33 40.05 44.30 +13.18%

Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)

The Statement of Profit and Loss reflects the transition from an operating loss of ₹16.80 Crores in FY 2024-25 to an operating profit before finance costs, exceptional items, and tax of ₹6.17 Crores in FY 2025-26. Total expenses contracted significantly from ₹97.76 Crores to ₹58.22 Crores.

Statement of Profit and Loss Line Items FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Revenue from Operations 59.40 75.00 -20.80%
Other Income 0.10 1.99 -94.97%
Total Income 59.50 76.99 -22.72%
Expenses
Cost of Materials Consumed 61.88 63.77 -2.96%
Changes in Inventories of Work-in-Progress and Stock-in-Trade (23.28) 6.47 N/M
Employee Benefits Expense 4.10 5.34 -23.22%
Finance Costs 4.89 3.98 +22.86%
Depreciation and Amortisation Expense 2.41 2.50 -3.60%
Other Expenses 8.22 15.70 -47.64%
Total Expenses 58.22 97.76 -40.45%
Profit / (Loss) Before Tax 1.28 (20.78) N/M
Tax Expense
Current Tax 0.00 0.00 N/M
Deferred Tax Expense / (Credit) 0.17 (0.58) N/M
Total Tax Expense 0.17 (0.58) N/M
Profit / (Loss) for the Year 1.11 (20.19) N/M
Other Comprehensive Income (OCI)
Re-measurement Gains / (Losses) on Defined Benefit Plans 0.66 0.15 +340.00%
Income Tax Effect on Above (0.17) (0.04) +325.00%
Total Other Comprehensive Income (Net of Tax) 0.49 0.11 +345.45%
Total Comprehensive Income for the Year 1.60 (20.08) N/M
Earnings Per Equity Share – Basic & Diluted (in ₹) 1.00 (20.89) N/M

The operational turnaround was supported by a structural reduction in other operating expenses, which fell from ₹15.70 Crores in FY 2024-25 to ₹8.22 Crores in FY 2025-26. Major cost reductions were achieved in power and fuel (reduced from ₹3.99 Crores to ₹1.99 Crores), contract labour wages (lowered from ₹3.72 Crores to ₹1.42 Crores), and repairs and maintenance (down from ₹2.84 Crores to ₹1.48 Crores), reflecting tightened cost controls across operational processes.

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

The company’s balance sheet expanded during FY 2025-26, driven by the successful rights issue that raised ₹29.96 Crores in fresh equity and securities premium. Total assets rose from ₹94.54 Crores as of March 31, 2025, to ₹124.78 Crores as of March 31, 2026.

Balance Sheet Schedule III Line Items As at March 31, 2026 (₹ in Crores) As at March 31, 2025 (₹ in Crores) Latest YoY (%)
ASSETS
Non-Current Assets
Property, Plant and Equipment 24.24 25.46 -4.79%
Financial Assets: Investments 0.19 0.21 -9.52%
Financial Assets: Other Financial Assets 0.83 0.81 +2.47%
Other Non-Current Assets 0.69 0.67 +2.99%
Total Non-Current Assets 25.95 27.15 -4.42%
Current Assets
Inventories 64.09 49.97 +28.26%
Financial Assets: Trade Receivables 11.40 13.25 -13.96%
Financial Assets: Cash and Cash Equivalents 16.70 0.31 +5287.10%
Financial Assets: Bank Balances Other than Cash & Cash Equivalents 0.38 0.36 +5.56%
Other Current Assets 6.26 3.51 +78.35%
Total Current Assets 98.83 67.39 +46.65%
TOTAL ASSETS 124.78 94.54 +31.99%
EQUITY AND LIABILITIES
Equity
Equity Share Capital 19.21 9.22 +108.35%
Other Equity 26.40 5.43 +386.19%
Total Equity (Net Worth) 45.60 14.65 +211.26%
Non-Current Liabilities
Non-Current Borrowings 10.21 3.79 +169.39%
Provisions 0.44 0.80 -45.00%
Deferred Tax Liabilities (Net) 1.25 0.91 +37.36%
Total Non-Current Liabilities 11.90 5.50 +116.36%
Current Liabilities
Current Borrowings 35.12 36.26 -3.14%
Trade Payables: Micro and Small Enterprises 9.69 6.22 +55.79%
Trade Payables: Creditors Other than Micro and Small Enterprises 15.65 27.39 -42.86%
Other Financial Liabilities 0.42 0.05 +740.00%
Other Current Liabilities 6.29 4.03 +56.08%
Provisions 0.12 0.44 -72.73%
Total Current Liabilities 67.28 74.39 -9.56%
TOTAL LIABILITIES 79.18 79.89 -0.89%
TOTAL EQUITY AND LIABILITIES 124.78 94.54 +31.99%

Working capital analysis reveals changes in asset composition:

  • Inventory Position: Inventories expanded by 28.26% to ₹64.09 Crores as at March 31, 2026 (from ₹49.97 Crores), driven by a build-up in work-in-process (₹50.03 Crores vs. ₹26.75 Crores) to support expanding order execution.
  • Trade Receivables & Collections: Trade receivables decreased to ₹1.14 Crores from ₹1.33 Crores, reflecting improved collection cycles. Receivable turnover accelerated to 4.82 times from 2.25 times.
  • Trade Payables Settlement: Total trade payables were reduced from ₹33.61 Crores to ₹25.33 Crores as the company deployed rights issue liquidity to settle vendor dues.
  • Statutory Ratio Movements: The Current Ratio strengthened to 1.47x from 0.91x, and the Debt-to-Equity Ratio improved from 2.73x to 0.99x following the equity recapitalisation.

Cash Flow: Tracking the Money Movement

The Statement of Cash Flows illustrates cash generation, investment allocations, and the financial impact of the FY 2025-26 recapitalisation.

Cash Flow Statement Components FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Profit / (Loss) Before Tax 1.28 (20.78) N/M
Operating Profit Before Working Capital Changes 8.49 (12.34) N/M
Net Cash Generated from / (Used in) Operating Activities Before Taxes (12.24) 11.61 N/M
Direct Taxes Paid (Net of Refunds) 0.00 (0.12) -100.00%
Net Cash Flows Generated from / (Used in) Operating Activities (12.24) 11.49 N/M
Purchase of Property, Plant and Equipment (CapEx) 1.20 1.05 +14.29%
Interest Received 0.10 (1.99) N/M
Movement in Other Bank Balances (0.02) (0.15) -86.67%
Net Cash Used in Investing Activities (1.11) (3.18) -65.09%
Proceeds from Issuance of Shares (Rights Issue) 10.57% 93.20% –
Share Issue Expenses (0.61) 0.00 N/M
Proceeds from Long-Term Borrowings 10.57% 93.20% –
Repayment of Long-Term Borrowings (4.66) (0.63) +639.68%
Repayment of Short-Term Borrowings (Net) (0.28) (3.82) -92.67%
Finance Costs / Interest Paid (4.89) (3.98) +22.86%
Net Cash Used in Financing Activities 29.74 (8.23) N/M
Net Increase / (Decrease) in Cash and Cash Equivalents 16.39 0.08 +20387.50%
Cash and Cash Equivalents at Beginning of the Year 0.31 0.23 +34.78%
Cash and Cash Equivalents at End of the Year 16.70 0.31 +5287.10%

Operating cash flow registered a net absorption of ₹12.24 Crores, compared to positive generation of ₹11.49 Crores in FY 2024-25. This cash outflow was primarily attributable to an intentional increase in inventory (₹14.12 Crores absorbed) and the reduction of trade payables by ₹8.28 Crores. The operational working capital build was fully financed by net equity receipts from the rights issue of ₹29.35 Crores (net of issue expenses of ₹0.61 Crores), elevating closing cash balances to ₹16.70 Crores.

Funding the Future: CapEx, CWIP, R&D & Foreign Exchange

Capital investments in tangible assets were maintained within available cash resources, focusing on process debottlenecking rather than uncommitted greenfield capacity expansion:

  • Capital Expenditure (CapEx): Tangible asset additions during FY 2025-26 stood at ₹1.20 Crores (FY 2024-25: ₹1.05 Crores), directed primarily toward plant and machinery enhancements (₹1.18 Crores) and computer/office automation systems.
  • Research and Development (R&D): As detailed in Section 31 of the Directors’ Report, specific capitalized R&D expenditure for the fiscal year was recorded as Nil. Technical product development and route-synthesis improvements were integrated into regular plant operations and batch engineering.
  • Foreign Exchange Inflow and Outgo: Both foreign exchange earnings and foreign exchange outgo were Nil for FY 2025-26 and FY 2024-25.

👥 Power & Control: Corporate Governance, Leadership & Ownership

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

The company maintains a governance framework compliant with the Companies Act, 2013, and SEBI Listing Regulations. The Board includes an executive management team and independent directors with backgrounds in chemistry, corporate law, finance, and industrial operations.

Name of Director / KMP Designation / Role DIN Category
Mr. Gaddam Venkata Ramana Managing Director 00031873 Executive / Promoter
Mr. Satyanarayana Raju Bhupathiraju Executive Director & CFO 02697880 Executive / Promoter
Mr. Rajesh Kumar Kathulla Whole Time Director 05349717 Executive Director
Mr. Dilip Vishnu Acharekar Independent Director 08849689 Non-Executive – Independent
Ms. Jasmin Kunal Tailor Independent Director 10794164 Non-Executive – Independent
Mr. Ranga Raju Alluri Non-Executive Director 07302447 Non-Executive – Non Independent
Mr. Premananda Reddy Vennapusa Non-Executive Director 02512956 Non-Executive – Non Independent
Mr. Avula Navaneeswara Reddy Additional Director (Appointed 14.10.2026) 12001029 Non-Executive – Non Independent

Who Owns the Stock? Shareholding Pattern

The shareholding structure of Vineet Laboratories underwent a significant expansion during FY 2025-26 as a consequence of the rights issue allotment completed on February 2, 2026, which issued 99,87,258 equity shares at ₹30 per share.

Category of Shareholder No. of Shares Held Percentage of Shareholding
Promoters and Promoter Group 11,49,097 5.98%
Foreign Portfolio / Institutional Investors (FPIs/FIIs) 68,999 0.36%
Resident Individuals (Public) 1,70,42,843 88.74%
Bodies Corporate 2,20,279 1.15%
Non-Resident Indians (NRIs) 3,37,937 1.76%
Hindu Undivided Families (HUFs) 2,93,297 1.53%
Unclaimed Suspense / Escrow Account 93,813 0.49%
Limited Liability Partnerships (LLP) 1 0.00%
Total Paid-Up Equity Share Capital 1,92,06,266 100.00%

Following the rights issue, total paid-up share capital increased from ₹9.22 Crores (92,19,008 equity shares) to ₹19.21 Crores (1,92,06,266 equity shares of face value ₹10 each). Notable individual shareholders include Mr. Arjun Aggarwal, who holds 21,80,000 equity shares representing 11.35% of the total issued equity capital as of March 31, 2026.

🗺️ The Corporate Family Tree: Group Structure & Strategic Investments

Subsidiaries, Associates, & Joint Ventures (Form AOC-1)

As documented in Section 15 of the Directors’ Report, Vineet Laboratories Limited does not maintain any subsidiary companies, associates, or joint ventures as defined under Section 2(87) and Section 2(6) of the Companies Act, 2013.

Entity Name Relationship Country % Shareholding Turnover (₹ in Crores) Profit / (Loss) After Tax (₹ in Crores)
None (Direct Standalone Operations Only) Not Applicable India 0.00% 0.00 0.00

Strategic Investments, Credit Facilities & Contingent Liabilities

The company maintains liquid investments, banking arrangements, and disclosure of debt structures:

  • Treasury & Mutual Fund Investments: Non-current investments comprise 21,469 units in regular Flexi-Cap Mutual Funds measured at fair value through profit and loss (FVTPL) with a carrying value of ₹0.19 Crores as at March 31, 2026 (down from ₹0.21 Crores as at March 31, 2025).
  • Banking Arrangements: Credit relationships are managed primarily through HDFC Bank Limited, which provides secured working capital credit facilities against hypothecation of current assets, plant and machinery, debtors, and stock, with working capital borrowings outstanding at ₹35.00 Crores as of year-end. Secured vehicle and equipment loans totaled ₹0.29 Crores.
  • Unsecured Promoter Loans: Long-term loans from directors and related parties stood at ₹1.00 Crores as of March 31, 2026 (increased from ₹0.71 Crores as of March 31, 2025), which are interest-free and unsecured.
  • Contingent Liabilities: Arrears of undisputed statutory dues outstanding for more than six months included Income Tax deducted at source (TDS) of ₹0.12 Crores for FY 2024-25. The company reported no pending litigation with adverse financial implications or outstanding corporate guarantees issued on behalf of third parties.

🎯 The Strategic Outlook: Competitive Moats, Risks & Future Growth Plans

Competitive Advantages & Economic Moats

Vineet Laboratories maintains specific operational capabilities that underpin its market presence:

  • Synthetic Process Chemistry: Technical capabilities in complex, multi-step organic synthesis enable the production of niche intermediates that require precise yield management and quality documentation.
  • Dual-Engine Exposure: Active participation across both pharmaceutical APIs and personal care specialty chemicals provides operational resilience, decoupling revenue streams from singular healthcare procurement cycles.
  • Lower Financial Gearing: The infusion of ₹29.96 Crores from the FY 2025-26 rights issue reduced the company’s debt-to-equity ratio to 0.99x, improving liquidity to support customer qualification requirements.

What Could Go Wrong? Key Challenges & Business Risks

The company faces notable operational and commercial risks:

  • Raw Material Price Volatility: Heavy dependence on Key Starting Materials (KSMs), basic organic chemicals, and solvents sourced from domestic and international markets exposes operations to margin contraction during price spikes.
  • High Customer Concentration: Intermediates manufacturing is subject to client concentration risks, where changes in purchasing patterns by primary formulators can impact quarterly capacity utilisation.
  • Evolving GMP Standards: Regulatory compliance mandates under the revised Schedule M of the Drugs and Cosmetics Rules, 1945, which became universally binding from January 1, 2026, require ongoing investments in quality systems and infrastructure.

The Next Chapter: Growth, Order Pipeline & CapEx Initiatives

Management’s forward strategy centers on three primary operational objectives:

  • Monetising Work-in-Process: Converting the ₹50.03 Crores of work-in-process inventory into finished goods to generate positive operating cash flow and lower reliance on working capital facilities.
  • Scale-up of Personal Care Ingredients: Expanding production runs for Piroctone Olamine and UV filters (Tinosorb S and Ethylhexyl Triazone) to meet demand from domestic and international cosmetic brand formulators.
  • Operational Deleveraging: Utilizing operational cash flows to reduce the ₹35.12 Crores in short-term bank borrowings and associated annual finance costs of ₹4.89 Crores.

The Verdict: Strategic Outlook & Conclusion

FY 2025-26 represented a stabilizing year for Vineet Laboratories Limited. By exiting unprofitable commodity product lines, the company restored positive operating profitability, achieving an EBITDA of ₹8.49 Crores and returning to net profitability at ₹1.11 Crores. Combined with the rights issue recapitalisation, which elevated net worth to ₹45.60 Crores, the company has repositioned its balance sheet to support steady execution across its higher-value pharmaceutical intermediate and personal care chemical portfolios.

Frequently Asked Questions (FAQs) About Vineet Laboratories

Q1: What is the core business of Vineet Laboratories Limited?

Vineet Laboratories Limited manufactures advanced pharmaceutical intermediates, bulk drugs, active pharmaceutical ingredient (API) precursors, and personal care specialty chemicals. Its portfolio includes intermediates for anti-retrovirals (Ritonavir, Lopinavir), anti-fungals (Voriconazole), ophthalmic solutions (Dorzolamide, Brinzolamide), and personal care actives such as Piroctone Olamine and modern UV filters.

Q2: What were the company’s revenue, operating profit, and net profit for FY 2025-26?

For the financial year ended March 31, 2026, Vineet Laboratories recorded revenue from operations of ₹59.40 Crores, an EBITDA of ₹8.49 Crores (operating margin of 14.29%), and a net profit after tax of ₹1.11 Crores, recovering from an operating loss in FY 2024-25.

Q3: Who manages Vineet Laboratories and what is its shareholding structure?

The company is managed by Mr. Gaddam Venkata Ramana (Managing Director) and Mr. Satyanarayana Raju Bhupathiraju (Executive Director & CFO). Following the rights issue in early 2026, the promoter and promoter group held 5.98% of the equity capital, institutional investors held 0.36%, and public resident individual and corporate shareholders held 93.66% of the 1,92,06,266 total shares.

Q4: Where are the manufacturing facilities of Vineet Laboratories located?

The company’s primary corporate office and manufacturing facilities are located in Hyderabad and the surrounding industrial corridors of Telangana, India. The facilities house chemical reaction lines, testing equipment, quality assurance laboratories, and effluent treatment systems.

Q5: How did the rights issue in FY 2025-26 affect the balance sheet?

The rights issue generated ₹29.96 Crores in fresh gross equity proceeds through the issuance of 99,87,258 shares at ₹30 per share. This transaction expanded total equity (net worth) from ₹14.65 Crores to ₹45.60 Crores, improved the current ratio from 0.91x to 1.47x, and lowered the debt-to-equity ratio from 2.73x to 0.99x.

Note: Financial ratios and percentage shares of total revenues have been calculated based strictly on the financial disclosures contained in the Vineet Laboratories Limited Annual Report for FY 2025-26.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://vineetlabs.co.in